Clinical trials: COVID-19
COVID-19 Vaccine
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
The objective of this study is to determine the safety and immunogenicity of two different strengths (4 µg and 6 µg) of an inactivated COVID-19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in…
- Trial name
- NCT04838080
- Testing
- Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine, Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kocak Farma
Covid19
Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects
Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.
- Trial name
- NCT04667442
- Testing
- Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Nanomix
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR C19 IL (NCT05712096)
- Testing
- EVUSHELD
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
COVID-19
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles…
- Trial name
- NCT05125562
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Covid19, Stage 1 Acute Kidney Injury
Phase 2a MIB-626 vs. Placebo COVID-19
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by…
- Trial name
- NCT05038488
- Testing
- MIB-626, Home Treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Metro International Biotech, LLC
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
This is prospective double-blind study in the United States is designed to investigate the efficacy and safety of a single dose of COVI-DROPS or matched placebo in outpatient adults with mild symptoms associated with COVID-19 and…
- Trial name
- US (NCT05074394)
- Testing
- COVI-DROPS
- Sponsor
- Sorrento Therapeutics, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
SARS-CoV-2
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04470427
- Testing
- mRNA-1273
- Where
- 100 sites in United States
- Volunteers
- 30,415 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid 19, Influenza
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
2. Participants will: Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. Visit the clinic on the 7th day of treatment for a check-up and safety tests.
- Trial name
- NCT06817096
- Volunteers
- 340 people
- Sponsor
- Azidus Brasil
Focus in on Collecting Paired Specimens for Matrix Equivalency
Specimen Collection Study Protocol
The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum.
- Trial name
- NCT04468386
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Biomerica
Coronavirus Infection COVID-19
Clinical Trial of a Medical Device "Device for Non-invasive Electromagnetic Therapy "TOR" in the Treatment of COVID-19"
A clinical trial was conducted with human participation in order to assess the safety and efficacy of the medical device "TOR device for non-invasive electromagnetic therapy" when used as an adjunct in combination with standard…
- Trial name
- NCT05220579
- Testing
- Exposure to "TOR" device, Exposure to switched off "TOR" device
- Where
- Russia
- Volunteers
- 236 people
- Sponsor
- Concern GRANIT
Post-Acute COVID-19 Syndrome
A Study of Apabetalone in Subjects With Long -COVID
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed…
- Trial name
- NCT06590324
- Testing
- Apabetalone
- Where
- 3 sites in Jordan, Saudi Arabia and 1 more
- Volunteers
- 200 people
- Sponsor
- Resverlogix Corp
COVID-19 Virus Infection, COVID-19
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC
A rapid point of care test for the detection of virus particles will be compared to the FDA approved EUA RT-PCR detection standard.
- Conditions
- COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic
- Trial name
- NCT05514691
- Testing
- iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp")
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Healthy Volunteers
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
This is a Phase 1, double-blind, randomized, placebo-controlled study to investigate single and multiple intravenous infusions of improved cell-permeable nuclear import inhibitor (iCP NI) in healthy subjects.
- Trial name
- NCT05740280
- Testing
- iCP-NI
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cellivery Therapeutics, Inc.
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
Covid19
Clinical Study Spartan COVID-19 V2 System (Canada Alternate)
This multicentre prospective study will enroll a sufficient number of patients to afford approximately 30 positives and > 30 negatives (as determined by the SOC - Comparator method) in the United States and/or Canada.
- Trial name
- NCT04628208
- Testing
- Spartan COVID-19 v2 System
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- Spartan Bioscience Inc.
COVID-19
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients.
- Trial name
- NCT05675748
- Testing
- Azvudine
- Volunteers
- 400 people
- Sponsor
- Shanghai Henlius Biotech
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.
- Trial name
- NCT04545749
- Testing
- UB-612
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.